Q-omics provides the consensus-scored MTPAP profile across patient tissues and cancer cell-line models. MTPAP expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MTPAP is differentially expressed in 15, with the highest sampling consensus in STAD. Additionally, MTPAP protein abundance shows 29,657 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, STAD, and LSCC as cancer lineages where MTPAP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTPAP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTPAP survival associations across molecular data types. MTPAP RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTPAP RNA expression–survival associations across cancer types. High MTPAP expression shows unfavorable associations in LIHC, ACC, UVM and KIRP, but favorable associations in KIRC and LGG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for MTPAP RNA expression.
This table summarizes MTPAP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 13. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MTPAP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTPAP shows lower tumor expression in THCA and higher tumor expression in STAD, LUAD, LIHC, COAD and LUSC. The STAD box plot shows higher MTPAP RNA expression in tumor versus normal tissue (log2 FC = +0.980, t-test p < 0.001).
This table shows molecular features associated with MTPAP in patient tissues and cancer cell lines. In patient samples, MTPAP shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MTPAP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
